Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $79.21 USD
Change Today +0.205 / 0.26%
Volume 19.7K
CLVS On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 9:42 AM 09/2/15 All times are local (Market data is delayed by at least 15 minutes).

clovis oncology inc (CLVS) Snapshot

Open
$80.00
Previous Close
$77.86
Day High
$81.15
Day Low
$78.74
52 Week High
05/14/15 - $102.28
52 Week Low
09/25/14 - $39.45
Market Cap
3.0B
Average Volume 10 Days
776.2K
EPS TTM
$-6.75
Shares Outstanding
38.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CLOVIS ONCOLOGY INC (CLVS)

clovis oncology inc (CLVS) Related Businessweek News

No Related Businessweek News Found

clovis oncology inc (CLVS) Details

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. It is developing three product candidates which include Rociletinib, an oral epidermal growth factor receptor and mutant-selective covalent inhibitor that is in advanced clinical development for the treatment of non-small cell lung cancer; Rucaparib, an oral inhibitor of poly polymerase, which is in advanced clinical development for the treatment of ovarian cancer; and Lucitanib, an oral inhibitor of the tyrosine kinase that is in Phase II development for the treatment of breast and lung cancers. The company's drug discovery program includes the discovery of cKIT inhibitor targeting resistance mutations for the treatment of GIST, a gastrointestinal cancer. It has license agreements with Advenchen Laboratories LLC, Avila Therapeutics, Inc., and Pfizer Inc.; collaboration and license agreement with Les Laboratoires Servier; a drug discovery collaboration agreement with Array BioPharma Inc.; collaboration with Foundation Medicine, Inc.; and clinical trial collaboration with Genentech for lung cancer treatment. Clovis Oncology, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.

136 Employees
Last Reported Date: 02/27/15
Founded in 2009

clovis oncology inc (CLVS) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $901.7K
Co-Founder, Chief Financial Officer, Executiv...
Total Annual Compensation: $575.2K
Co-Founder, Chief Regulatory Officer and Exec...
Total Annual Compensation: $575.2K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $473.4K
Compensation as of Fiscal Year 2014.

clovis oncology inc (CLVS) Key Developments

Clovis Oncology, Inc. Announces Resignation of Andrew Allen as Executive Vice President of Clinical & Pre-Clinical Development & Chief Medical Officer

Dr. Andrew Allen resigned from the position of Executive Vice President of Clinical & Pre-Clinical Development & Chief Medical Officer of Clovis Oncology, Inc. effective July 31, 2015.

Clovis Oncology Enters into Clinical Trial Collaboration with Genentech for Lung Cancer Treatment

Clovis Oncology announced that it has entered into a clinical trial collaboration with Genentech, a member of the Roche Group, to evaluate a novel combination therapy of Genentech's investigational cancer immunotherapy atezolizumab and rociletinib for the treatment of advanced EGFR-mutant non-small cell lung cancer. The Phase 1b/2 trial of rociletinib in combination with atezolizumab is planned to begin enrolling patients before the end of 2015. The trial, sponsored by Clovis, is designed to assess the safety and activity of the combination in patients with advanced or metastatic non-small cell lung cancer. The Phase 1b portion of the trial will evaluate the safety, tolerability and pharmacokinetics of the combination in this population while the Phase 2 portion of the trial will evaluate the activity of the combination in two subgroups of patients.

Clovis Oncology, Inc. Announces Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Clovis Oncology, Inc. announced consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported operating loss was $68,336,000 compared to $34,966,000 a year ago. Loss before income taxes was $71,513,000 compared to $34,696,000 a year ago. Net loss was $71,531,000 or $2.10 basic and diluted per share compared to $34,764,000 or $1.03 basic and diluted per share a year ago. For the six months, the company reported operating loss was $132,561,000 compared to $63,449,000 a year ago. License and milestone revenue was $0 compared to $13,625,000 a year ago. Loss before income taxes was $134,555,000 compared to $63,285,000 a year ago. Net loss was $134,675,000 or $3.96 basic and diluted per share compared to $65,482,000 or $1.93 basic and diluted per share a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CLVS:US $79.21 USD +0.205

CLVS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CLVS.
View Industry Companies
 

Industry Analysis

CLVS

Industry Average

Valuation CLVS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 13.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CLOVIS ONCOLOGY INC, please visit www.clovisoncology.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.